TY - JOUR T1 - Clonal hematopoiesis is associated with protection from Alzheimer’s disease JF - medRxiv DO - 10.1101/2021.12.10.21267552 SP - 2021.12.10.21267552 AU - Hind Bouzid AU - Julia A. Belk AU - Max Jan AU - Yanyan Qi AU - Chloé Sarnowski AU - Sara Wirth AU - Lisa Ma AU - Matthew Chrostek AU - Herra Ahmad AU - Daniel Nachun AU - Winnie Yao AU - NHLBI Trans-omics for Precision Medicine (TOPMed) Consortium AU - Alexa Beiser AU - Alexander G. Bick AU - Joshua C. Bis AU - Myriam Fornage AU - William T. Longstreth, Jr. AU - Oscar L. Lopez AU - Pradeep Natarajan AU - Bruce M. Psaty AU - Claudia L. Satizabal AU - Joshua Weinstock AU - Eric B. Larson AU - Paul K. Crane AU - C. Dirk Keene AU - Sudha Seshadri AU - Ansuman T. Satpathy AU - Thomas J. Montine AU - Siddhartha Jaiswal Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/13/2021.12.10.21267552.abstract N2 - Clonal hematopoiesis of indeterminate potential (CHIP) is a pre-malignant expansion of mutated blood stem cells that also associates with non-hematological disorders. Here, we tested whether CHIP was associated with Alzheimer’s disease (AD). Surprisingly, we found that CHIP carriers had reduced risk of AD dementia or AD neuropathologic features in multiple cohorts. The same mutations found in blood were also detected in the microglia-enriched fraction of brain in 7 out of 8 CHIP carriers. Single-cell chromatin accessibility profiling of brain-derived nuclei in two CHIP carriers revealed that the mutated cells were indistinguishable from microglia and comprised between 42-77% of the total microglial pool. These results suggest a role for mutant, marrow-derived cells in attenuating risk of AD, possibly by supplementing a failing microglial system during aging.Competing Interest StatementA.T.S. is a founder of Immunai and Cartography Biosciences and receives research funding from 10x Genomics, Arsenal Biosciences, and Allogene Therapeutics. S.J. is a scientific advisor to Novartis, Roche Genentech, AVRO Bio, and Foresite Labs. P.N. reports investigator-initiated grants from Amgen, Apple, AstraZeneca, Novartis, and Boston Scientific, personal fees from Blackstone Life Sciences, Apple, AstraZeneca, Novartis, Genentech, and Foresite Labs, and spousal employment at Vertex, all unrelated to the present work.Funding StatementThis work was supported by grants to S.J. from the Burroughs Wellcome Fund Career Award for Medical Scientists, Fondation Leducq (TNE-18CVD04), the Ludwig Center for Cancer Stem Cell Research at Stanford University, and the National Institutes of Health (DP2-HL157540), to S.J. and H.B. from the National Institutes of Health (R01-HL148565), to T.J.M. from the National Institutes of Health (AG053959), to C.D.K.from the Nancy and Buster Alvord Endowment, to A.T.S. from the National Institutes of Health K08CA230188 and the Burroughs Wellcome Fund Career Award for Medical Scientists, to P.N. from the National Institutes of Health (R01HL142711, R01HL148050, R01HL151283, R01HL148565, R01HL135242, R01HL151152,R01DK125782), Fondation Leducq (TNE-18CVD04), and MGH (Fireman Endowed Chair in Vascular Medicine).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Stanford University waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data from TOPMed and ADSP are available on dbGaP for investigators with approved protocols. Single-cell ATAC-seq data generated here from human brain samples will be deposited in Gene Expression Omnibus. ER -